Skip to main content

HbAHP-25, a peptide designed in silico, exhibits potent anti-HIV activity in vitro


Identifying and / or designing molecules that can inhibit HIV infection and be safe to the host cells is highly desired.


HbAHP-25 was designed in silico against CD4 binding domain of gp120 of HIV-1 by molecular docking using Z dock and PROSA softwares. ELISA and SPR were used to determine the binding ability of HbAHP-25 to gp120. Anti-HIV activity of this peptide was checked by two different assays, viz: a) On TZM bl cells, using luciferase assay; b) On CEM-GFP cells and PBMCs using p24 antigen assay. MTT assay, TER/microsphere assay and Immunofluorescence were used to determine the effect of HbAHP-25 on cell viability, epithelial monolayer integrity and permeability.


Five peptides were designed, and one of the peptides, HbAHP-25 , exhibits significant anti-HIV activity against various strains of HIV-1, such as HIV-1 Ada, HIV-1 NL4-3, and HIV-1 IIIB. ELISA and SPR revealed a direct interaction between HbAHP-25 and gp120, thereby inhibiting its interaction with CD4 receptor. The peptide didn’t affect cell viability even at higher concentrations; nor did it affect epithelial monolayer integrity or permeability. HbAHP-25 also did not interfere with any tight junction proteins such as ZO-1 and Clauddin-1, thus maintaining cell integrity as well.


The peptide has potent anti-HIV activity, and can be explored as a potential therapeutic /prophylactic/preventive agent.

Author information



Corresponding author

Correspondence to KVR Reddy.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bashir, T., Kumar, C. & Reddy, K. HbAHP-25, a peptide designed in silico, exhibits potent anti-HIV activity in vitro. BMC Infect Dis 14, E30 (2014).

Download citation


  • Peptide
  • Tight Junction
  • Molecular Docking
  • Tight Junction Protein
  • Affect Cell Viability